Predict benefit from brain stimulation
- Trial ID
- NCT07376278
- Official Title
- A Prospective Observational Study for the Predictors of Clinical Outcomes of Deep Brain Stimulation in Parkinson's Disease
- Goal
- Predict benefit from brain stimulation
- Status
- RECRUITING
- Sponsor
- Hong Kong University of Science and Technology
- Study Type
- OBSERVATIONAL
- Enrollment
- 30 participants
- Conditions
- Deep Brain Stimulation, PARKINSON DISEASE (Disorder)
- Interventions
- DBS
Plain-Language Summary
The study aims to find clinical, imaging, or blood markers that predict who will get the best motor and overall benefits from deep brain stimulation in Parkinson's. Participants are people already referred for standard DBS surgery, which uses implanted electrodes to send continuous electrical stimulation to brain targets such as the subthalamic nucleus or globus pallidus interna, calming abnormal movement circuits, improving tremor and slowness, and often allowing lower levodopa doses while treating dopamine-responsive symptoms. They are looking for adults 18 to 75 with clinically established, dopamine-responsive PD who have significant motor complications despite optimized meds, typically an off-med UPDRS motor score above 30, Hoehn and Yahr stage over 2.5 off meds, no major cognitive or psychiatric problems, and willingness to undergo DBS and blood sampling. The study is observational and plans to follow about 30 people to learn who benefits most rather than testing a new device.
Locations
- The Hong Kong University of Science and Technology, Hong Kong, Hong Kong
Frequently Asked Questions
- What is this trial testing?
- This trial is studying DBS. The study aims to find clinical, imaging, or blood markers that predict who will get the best motor and overall benefits from deep brain stimulation in Parkinson's. Participants are people already referred for standard DBS surgery, which uses implanted electrodes to send continuous electrical stimulation to brain targets such as the subthalamic nucleus or globus pallidus interna, calming abnormal movement circuits, improving tremor and slowness, and often allowing lower levodopa doses while treating dopamine-responsive symptoms. They are looking for adults 18 to 75 with clinically established, dopamine-responsive PD who have significant motor complications despite optimized meds, typically an off-med UPDRS motor score above 30, Hoehn and Yahr stage over 2.5 off meds, no major cognitive or psychiatric problems, and willingness to undergo DBS and blood sampling. The study is observational and plans to follow about 30 people to learn who benefits most rather than testing a new device.
- Who can participate?
- Participants must be between 18 Years and 75 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 10 years.